AU2017319135B2 - Aminopyrimidines as ALK inhibitors - Google Patents

Aminopyrimidines as ALK inhibitors Download PDF

Info

Publication number
AU2017319135B2
AU2017319135B2 AU2017319135A AU2017319135A AU2017319135B2 AU 2017319135 B2 AU2017319135 B2 AU 2017319135B2 AU 2017319135 A AU2017319135 A AU 2017319135A AU 2017319135 A AU2017319135 A AU 2017319135A AU 2017319135 B2 AU2017319135 B2 AU 2017319135B2
Authority
AU
Australia
Prior art keywords
phenyl
isopropoxy
tetrahydropyridin
isopropylsulfonyl
diamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017319135A
Other languages
English (en)
Other versions
AU2017319135A1 (en
Inventor
Jianyong Chen
Shaomeng Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan (System)
Original Assignee
University of Michigan (System)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan (System) filed Critical University of Michigan (System)
Publication of AU2017319135A1 publication Critical patent/AU2017319135A1/en
Application granted granted Critical
Publication of AU2017319135B2 publication Critical patent/AU2017319135B2/en
Priority to AU2021203098A priority Critical patent/AU2021203098B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017319135A 2016-08-29 2017-08-28 Aminopyrimidines as ALK inhibitors Active AU2017319135B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021203098A AU2021203098B2 (en) 2016-08-29 2021-05-14 Aminopyrimidines as ALK inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662380818P 2016-08-29 2016-08-29
US62/380,818 2016-08-29
PCT/US2017/048845 WO2018044767A2 (en) 2016-08-29 2017-08-28 Aminopyrimidines as alk inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021203098A Division AU2021203098B2 (en) 2016-08-29 2021-05-14 Aminopyrimidines as ALK inhibitors

Publications (2)

Publication Number Publication Date
AU2017319135A1 AU2017319135A1 (en) 2019-04-04
AU2017319135B2 true AU2017319135B2 (en) 2021-03-18

Family

ID=59846649

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017319135A Active AU2017319135B2 (en) 2016-08-29 2017-08-28 Aminopyrimidines as ALK inhibitors
AU2021203098A Active AU2021203098B2 (en) 2016-08-29 2021-05-14 Aminopyrimidines as ALK inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021203098A Active AU2021203098B2 (en) 2016-08-29 2021-05-14 Aminopyrimidines as ALK inhibitors

Country Status (11)

Country Link
US (2) US10709705B2 (enExample)
EP (2) EP3504203B1 (enExample)
JP (2) JP7094566B2 (enExample)
KR (1) KR102530871B1 (enExample)
CN (2) CN115043821B (enExample)
AU (2) AU2017319135B2 (enExample)
IL (1) IL264638B (enExample)
MX (2) MX389265B (enExample)
NZ (1) NZ751713A (enExample)
SG (2) SG11201901251SA (enExample)
WO (1) WO2018044767A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI726363B (zh) * 2018-07-31 2021-05-01 大陸商蘇州亞盛藥業有限公司 Fak/alk/ros1抑制劑與egfr抑制劑的組合治療癌症的方法
CN111171033B (zh) * 2018-11-09 2021-11-02 天津大学 一种嘧啶衍生物及其合成方法和应用
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN110143947B (zh) * 2019-05-29 2021-10-15 华东师范大学 一种色瑞替尼类似物的制备方法
US20220117964A1 (en) * 2019-06-25 2022-04-21 Ascentage Pharma (Suzhu) Co., Ltd. Combination of fak inhibitor and btk inhibitor for treating a disease
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20230381176A1 (en) * 2020-09-25 2023-11-30 Ascentage Pharma (Suzhou) Co., Ltd. A pharmaceutical composition and use thereof for treatment of cancer
WO2022222932A1 (en) * 2021-04-19 2022-10-27 Ascentage Pharma (Suzhou) Co., Ltd. A pharmaceutical combination and use thereof
CA3238857A1 (en) * 2021-12-09 2023-06-15 Oncobix Co., Ltd. Novel heterocyclic-substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect, and pharmaceutical composition containing same
CN116332919B (zh) * 2022-03-30 2025-08-26 苏州亚盛药业有限公司 一种alk抑制剂化合物及其中间体的制备方法
WO2024153228A1 (zh) * 2023-01-20 2024-07-25 苏州亚盛药业有限公司 Alk抑制剂或其盐、溶剂合物的结晶形式及其制备方法和应用
AU2024238523A1 (en) * 2023-03-22 2025-10-09 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition and use thereof
WO2025157162A1 (zh) 2024-01-22 2025-07-31 应世生物科技(南京)有限公司 Fak抑制剂与kras g12c抑制剂的联用
WO2025232723A1 (en) * 2024-05-06 2025-11-13 Ascentage Pharma (Suzhou) Co., Ltd. Treatment method with focal adhesion kinase inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012106540A1 (en) * 2011-02-02 2012-08-09 Irm Llc Methods of using alk inhibitors
WO2015081813A1 (zh) * 2013-12-03 2015-06-11 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
WO2015130014A1 (ko) * 2014-02-28 2015-09-03 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
ATE542801T1 (de) 2003-08-15 2012-02-15 Novartis Ag Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
AU2004272288B2 (en) * 2003-09-18 2008-11-13 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
PL2253614T3 (pl) * 2004-04-07 2013-03-29 Novartis Ag Inhibitory IAP
EA019941B1 (ru) 2006-12-08 2014-07-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
AU2009233964B2 (en) 2008-04-07 2012-06-07 Irm Llc Compounds and compositions as protein kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
KR20130139999A (ko) 2010-10-14 2013-12-23 어리어드 파마슈티칼스, 인코포레이티드 Egfr-유도된 암의 세포 증식을 억제하는 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012106540A1 (en) * 2011-02-02 2012-08-09 Irm Llc Methods of using alk inhibitors
WO2015081813A1 (zh) * 2013-12-03 2015-06-11 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
WO2015130014A1 (ko) * 2014-02-28 2015-09-03 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물

Also Published As

Publication number Publication date
AU2021203098B2 (en) 2023-05-25
CN109715620B (zh) 2022-05-06
US10709705B2 (en) 2020-07-14
CN115043821B (zh) 2024-08-06
EP4001273A3 (en) 2022-08-24
US20200330464A1 (en) 2020-10-22
WO2018044767A2 (en) 2018-03-08
JP2022120151A (ja) 2022-08-17
KR102530871B1 (ko) 2023-05-09
CN109715620A (zh) 2019-05-03
JP7094566B2 (ja) 2022-07-04
EP4001273A2 (en) 2022-05-25
EP3504203A2 (en) 2019-07-03
SG11201901251SA (en) 2019-03-28
SG10201914030UA (en) 2020-03-30
NZ751713A (en) 2022-07-01
US20190175595A1 (en) 2019-06-13
MX389265B (es) 2025-03-20
IL264638B (en) 2021-08-31
US11110090B2 (en) 2021-09-07
CA3033223A1 (en) 2018-03-08
WO2018044767A3 (en) 2018-04-12
AU2017319135A1 (en) 2019-04-04
BR112019003897A2 (pt) 2019-05-21
KR20190039760A (ko) 2019-04-15
CN115043821A (zh) 2022-09-13
JP2019528307A (ja) 2019-10-10
MX2019002393A (es) 2019-07-08
MX2022000376A (es) 2022-02-10
EP3504203B1 (en) 2022-09-28
AU2021203098A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
AU2021203098B2 (en) Aminopyrimidines as ALK inhibitors
WO2019179482A1 (en) 5, 6-dihydro-11h-indolo [2, 3-b] quinolin-11-one compounds as alk inhibitors
US11168082B2 (en) Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors
US11045448B2 (en) Piperidines as covalent menin inhibitors
US20240150360A1 (en) Small Molecule Degraders of CBP/p300 Proteins
US20210115018A1 (en) Piperidine compounds as covalent menin inhibitors
US11944614B2 (en) Imidazo[4,5-c]pyridine compounds as LSD-1 inhibitors
EP3262045A1 (en) 9h-pyrimido [4,5-b]indoles as bet bromodomain inhibitors
US10781208B2 (en) 5,6-dihydro-11H-indolo[2,3-B]quinolin-11-ones as alk inhibitors
CA3033223C (en) Aminopyrimidines as alk inhibitors
HK40077976A (en) Aminopyrimidines as alk inhibitors
HK40026020A (en) Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors
HK40026020B (en) Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors
BR112019003897B1 (pt) Compostos de aminopirimidinas como inibidores de alk, composição farmacêutica bem como seus usos

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)